Cited up until very recently by Acorda Therapeutics Inc. as one of four late-stage pipeline candidates that would dramatically increase the company's product sales, the Phase III Plumiaz is being discontinued after it failed to demonstrate bioequivalence to the reference product.
The Ardsley, N.Y., biotech announced its decision May 20, noting that its nasal spray formulation of diazepam did not demonstrate...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
